Researchers at the University of Colorado Anschutz Linda Crnic Institute for Down Syndrome (Crnic Institute) have uncovered compelling evidence that individuals with Down syndrome experience ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects healthy upside for Novo Nordisk stock through ...

IT should be the most exciting time in his life – his first toy range has just been released, his latest video has already ...

After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will ...

Scientists have long known that inherited neurodegenerative disorders, including Alzheimer's, Parkinson's or motor neuron ...

A student discovered connection, access and belonging as he navigated the Everglades and other natural and manmade wonders ...

Baylor College of Medicine’s board of trustees named Dr. Jakub Tolar the next president, CEO and executive dean of the ...

Biology Viva Questions Class 12: The Class 12 Biology practical examination plays a crucial role in the board results, and ...

MONTREAL, /CNW/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, ...

Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1 ...

U.S. Patent No. 12,329,781 relates to Minovia’s proprietary mitochondrial augmentation technology for the treatment of renal diseases, including renal tubulopathy, kidney insufficiency, and chronic ...

The Company finishes 2025 with strong Q4 performance, expects 20-22% revenue growth in 2026, and promotes Ross Muken to ...